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Abstract
Background: Lymphazurin 1% blue dye can cause a severe anaphylactic reaction in approximately
1–3% of patients.
Case presentation: We describe a case of intraoperative anaphylaxis resulting from Lymphazurin
1% blue dye. A 48-year old woman undergoing a mastectomy with sentinel lymph node biopsy
experienced a biphasic anaphylactic reaction with two episodes of hypotension at 15 minutes and
2 hours, respectively, after injection of the blue dye. The late phase was initially refractory to
epinephrine.
Conclusion: Early recognition, aggressive hemodynamic management, and prolonged monitoring
are indicated in these patients to watch for a potential second phase anaphylactic reaction.
Background
Sentinel lymph node biopsy (SLNB) has emerged as the
standard procedure for staging of the axilla in patients
with clinically node-negative breast cancer [1,2]. This pro-
cedure serves as an alternative to routine axillary lymph
node dissection [3]. The sentinel lymph node is usually
located by intraparenchymal injection of blue dye alone
or in combination with intradermal administration of a
radiolabeled colloid near the tumor site. In breast cancer,
the combination of blue dye and radiotracer has been
shown to markedly increase the sensitivity of SLNB [4-9].
Approximately 50% of the dye is weakly bound to serum
albumin and is therefore selectively absorbed by lym-
phoid tissue [10,11]. The albumin-blue dye complex is
picked up by regional afferent lymphatics, which causes
lymphatic vessels and nodes to be identifiable by their
bright blue color.
Lymphazurin 1%, also known as isosulfan blue, is the
most commonly used blue dye in the United States.
Severe allergic reaction and anaphylaxis have been
observed in 1–3% of patients who are exposed to the dye
during SLNB [12-14]. These allergic reactions can range
from a mild allergic reaction characterized by urticaria
and/or erythema, to anaphylaxis that is associated with
hypotension, pulmonary edema, and/or cardiovascular
collapse. Some investigators have advocated preoperative
prophylaxis with steroids, diphenhydramine, and famoti-
dine, with reported reductions in the severity but not the
incidence of anaphylaxis [15]. The following case report
describes an episode of severe anaphylaxis characterized
by biphasic hypotension that occurred after intraparen-
chymal injection of Lymphazurin 1% for identification of
the sentinel lymph node. The literature on the manage-
ment of severe reactions is subsequently reviewed.
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Case presentation
A 48-year old woman was being treated for a malignant
neoplasm of her left breast. The tumor was a moderately
differentiated invasive ductal carcinoma (clinically T1
N0) that was discovered on physical examination and
identified on subsequent mammogram. The various sur-
gical options were discussed in depth with the patient,
who decided not to undergo a breast conservation proce-
dure or breast reconstruction. In addition, she elected to
undergo a contralateral prophylactic mastectomy in order
to address the approximate 0.5 – 1% per year risk of breast
cancer in the unaffected breast. Therefore, her operative
procedure was scheduled as a left modified radical mas-
tectomy with SLNB and right prophylactic mastectomy.
Her past medical history included migraine headaches
and chronic sinus infections. Her past surgical history was
significant for tonsillectomy, ankle surgery, dilation and
curettage, and sinus surgery, all of which were performed
under general anesthesia. The patient reported no drug,
food, or other allergies. No previous perioperative anes-
thetic complications were reported by the patient.
On the morning of surgery, the patient was premedicated
with 2 mg midazolam intravenously prior to the induc-
tion of anesthesia. General anesthesia was induced using
fentanyl, propofol, and rocuronium, after which the
patient was intubated in standard fashion. Anesthesia was
maintained with nitrous oxide, oxygen, and isoflurane.
The patient's left breast was then injected intraparenchy-
mally with 5 mL of Lymphazurin 1% blue dye, which was
followed by 5 minutes of light breast massage to mobilize
the dye. Approximately 15 minutes later, after her chest
wall had been prepped and draped, the patient experi-
enced an acute episode consistent with cardiovascular col-
lapse that was characterized by O2  desaturation and
systolic blood pressures in the range of 30–40 mm Hg.
The surgical procedure was halted (no incision had been
made) and the patient was placed in the Trendelenburg
position and given 100% oxygen. The possibility of a ten-
sion pneumothorax was eliminated by physical examina-
tion, which revealed robust breath sounds bilaterally.
Intravenous fluids were administered (~2000 cc total) and
0.1 mg epinephrine (1:10 000) was given intravenously.
Decadron (100 mg) and diphenhydramine (50 mg) were
administered when the blood pressure failed to improve.
She exhibited hives on her lower extremities bilaterally,
but there was no blue discoloration to the skin. The
patient was diagnosed with an anaphylactic reaction to
the blue dye after these events. Her blood pressure stabi-
lized and at that point she was placed on an epinephrine
drip at 2 μg/min. The patient was then transferred to the
surgical intensive care unit (SICU) for hemodynamic
monitoring and ventilation management.
Approximately 2 hours after injection of the blue dye, the
patient experienced a second hypotensive episode during
which her systolic blood pressure dropped to 65 mm Hg.
She received additional fluid resuscitation along with 50
mg benadryl, and the epinephrine drip was increased to 4
μg/min. The patient soon stabilized and the epinephrine
was weaned the next day. She was discharged from the
SICU 36 hours after admission. She was maintained on
methylprednisolone, diphenhydramine, and famotidine,
and given instructions on the use of an epinephrine pen
and albuterol inhaler. The patient did well and exhibited
no further allergic symptoms. She underwent the planned
surgery 2 weeks later utilizing radioactive colloid alone to
identify the sentinel lymph node. Two sentinel lymph
nodes were identified that were negative for metastatic
disease. Further examination of the lymph node speci-
mens revealed a 3 mm metastatic focus in the first lymph
node and a 6 mm metastatic focus in the second. The
patient underwent completion lymphadenectomy 4
weeks later.
Discussion
Lymphazurin 1% is the first dye of its type to be approved
by the Food and Drug Administration for visualization of
lymphatic tissues [16]. It is an aniline dye (2,5-disul-
fonated isomer of patent blue dye) with no known phar-
macological action [17]. As described previously,
approximately 50% of the total injection will weakly bind
to serum proteins and will be selectively absorbed by the
lymphatic vessels, allowing for identification of sentinel
lymph nodes. Ninety percent of the blue dye is excreted
via the biliary route, while 10% is excreted unchanged in
the urine. Use of this dye is contraindicated in those indi-
viduals with a known hypersensitivity to triphenylmeth-
ane or related compounds (package insert). However, due
to its widespread use outside medicine, including incor-
poration into textile dyes, cosmetics, hand lotions, house-
hold products, and paper, exposure and subsequent
sensitization is likely to have occurred in a significant pro-
portion of the population [18].
Anaphylactic reactions to the blue dye have been previ-
ously reported [10,11,16,19-21]. The incidence continues
to increase due to the more frequent use of blue dye to
delineate lymphatic spread of cancerous cells. In the oper-
ating room, the recognition of systemic anaphylaxis dur-
ing general anesthesia depends almost entirely on the
observation of clinical features in association with the
temporal exposure to a foreign substance. Rather than lab-
oratory tests, it is usually determined based upon clinical
observations such as urticaria, erythema, respiratory com-
plications, and/or cardiovascular collapse [22,23]. In
most reported cases, patients develop symptoms within
30 minutes of blue dye injection. The patient in this report
experienced a rapid decrease in blood pressure with aWorld Journal of Surgical Oncology 2008, 6:79 http://www.wjso.com/content/6/1/79
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systolic pressure declining to 40 mm Hg within minutes
after the injection of 5 mL of Lymphazurin 1%. Numerous
cases have been reported in which patients display a sys-
temic urticarial rash with blue coloration from the blue
dye along with the anaphylactic reaction, but these events
may also occur independently of each other [24]. The
present case differs in that the patient exhibited hives
bilaterally on her lower extremities (these were initially
hidden by sequential compression devices), but there was
no blue skin discoloration.
Although rare, anaphylactic shock after administration of
blue dye for SLNB is a potentially lethal situation. Early
recognition as well as aggressive hemodynamic manage-
ment of these reactions can dramatically reduce morbidity
and mortality [25]. In general, initial treatment modalities
should be targeted toward blood pressure management
and airway support. All anesthetic agents should be
immediately discontinued and 100% oxygen and rapid
intravenous infusion of crystalloids should be promptly
instituted. For initial pharmacologic management of
acute anaphylaxis, epinephrine should be administered
immediately [26]. Studies have shown that a delay in the
administration of epinephrine, the use of an inadequate
amount of epinephrine during the first phase, or a
requirement of large doses of epinephrine to ameliorate
the initial response might predispose to a biphasic
response [26-29]. While epinephrine has not been shown
to consistently prevent the second reaction, it remains the
treatment of choice for anaphylactic reactions. Intrave-
nous epinephrine (1:10 000) is typically only adminis-
tered in severe hypotensive shock, as in this case, because
of the potential for inducing tachyarrhythmias. Intrave-
nous antihistamines (H1 and H2 blockers) should be
considered next if the reaction persists because they can
reverse the effects of systemic histamine release and
thereby alter vascular permeability and systemic hemody-
namics [22,23,30,31]. Corticosteroids can also be given
concurrently to minimize or prevent the second phase
reaction of anaphylaxis, as this has been demonstrated to
be beneficial in some individuals [32-35]. There is no con-
sensus as to whether the administration of corticosteroids
affects the incidence of a late reaction. Of note, there have
also been several documented cases of patients who
received corticosteroid therapy and still went on to expe-
rience biphasic reactions [35-37].
We report a case in which a patient experienced a biphasic
anaphylactic reaction to Lymphazurin 1% blue dye during
SLNB. Interestingly, the second hypotensive episode
occurred within 1 hour of successful management of the
first phase. Corticosteroids were administered in this case,
but did not prevent a biphasic reaction in our patient.
Moreover, this late phase reaction was initially refractory
to epinephrine as the patient was already on an epine-
phrine drip when the late phase of her anaphylactic reac-
tion occurred. Biphasic anaphylactic reactions in which
late recurrences of hypotension occur several hours after
the acute episode have been previously reported. Albo et
al. described two patients who experienced biphasic ana-
phylactic reactions. In both cases, the first episode of ana-
phylaxis was managed by administration of crystalloid,
phenylephrine, epinephrine, hydrocortisone, and
diphenhydramine. Both patients had a second episode of
anaphylaxis during postoperative monitoring (6 hours
and 8 hours after surgery, respectively). The severity of
their second reactions was not reported, but they were
both treated successfully with an epinephrine bolus and
infusion of 1000 cc of crystalloid. Beenen et al. described
a patient who experienced a second period of hypoten-
sion [38]. After injection of the blue dye, a severe decline
in the blood pressure was witnessed. This initial anaphy-
lactic reaction was controlled with ephedrine, tavegyl, and
prednisone. The patient recovered and a SLNB was per-
formed, but when the surgeon wanted to continue with
resection of the left breast, a second period of hypoten-
sion occurred. No urticaria was observed and this subse-
quent episode was successfully treated with epinephrine.
These biphasic anaphylactic reactions could be caused by
delayed systemic release of antigen stores from the tissue
compartment back into the circulation once the circulat-
ing levels of blue dye begin to undergo clearance from the
bloodstream. Another suggested mechanism for the sec-
ond phase of anaphylaxis is due to the recruitment of late
inflammatory mediators, including prostaglandins, leu-
kotrienes, and nitric oxide.
Thus, patients who exhibit any sort of hemodynamic
instability should not go on to have further surgery at that
same setting. Also, a longer period of observation of up to
24 hours is indicated in patients who experience an ana-
phylactic reaction to blue dye before the episode should
be considered fully resolved [13,18,39].
Conclusion
As the use of Lymphazurin 1% for SLNB in the staging and
management of breast cancer becomes increasingly com-
mon, we will likely see an accompanying rise in the inci-
dence of anaphylactic reactions to blue dye. It is essential
that the personnel involved in the performance of those
procedures involving blue dye for lymphatic visualization
are aware of and prepared to recognize and treat anaphy-
laxis. Most importantly, this case report highlights the
need for extended observation and careful monitoring of
these patients for the possibility of biphasic anaphylactic
reaction that may occur hours after the apparent resolu-
tion of an acute episode of anaphylaxis to blue dye.
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